6-K - Molecular Partners AG | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Molecular Partners AG published the invitation to its 2026 Annual General Meeting on April 14, 2026, and proposed Clare Fisher for election to the Board of Directors while Steven H. Holtzman will not stand for re-election.

Key Takeaways

1Annual General Meeting scheduled for April 14, 2026, at 9:00 am CET at JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland.

2Clare Fisher nominated for election to Board of Directors; currently SVP Global Business Development and M&A at BeOne Medicines.

3Steven H. Holtzman, current Board member, will not stand for re-election after 12 years of service.

4Clare Fisher has over two decades of experience in biotech business development, including roles at Shire plc, Kaleido, Cubist, Blueprint Medicines, and Genzyme.

5Financial calendar includes Interim Management Statement Q1 2026 on May 12, 2026, and Half-year results 2026 on August 25, 2026.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Executive & Director Changes

Clare Fisher

Board of Directors

nominated for election

Effective: 2026-04-14

Steven H. Holtzman

Board of Directors

not standing for re-election

Effective: 2026-04-14

after 12 years of service

Exhibits (2)

6-K

99.1

EX-99.1